Related Experiment Video

Updated: Nov 4, 2025

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.2K

Small-Molecule Inhibitors Targeting eIF4A in Leukemia

Xiaofeng Jia1, Hong Zhou2

  • 1College of Life Sciences, China Jiliang University, Hangzhou 310018, China.

Current Protein & Peptide Science
|May 27, 2021
PubMed

Insights

Eukaryotic translation initiation factor 4A (eIF4A), a key RNA helicase, is crucial for cancer progression. Targeting eIF4A with small-molecule inhibitors shows promise for developing new cancer therapies.

Area of Science:

  • Molecular Biology
  • Biochemistry
  • Oncology

Background:

  • Eukaryotic translation initiation factor 4A (eIF4A) is a conserved DEAD-box RNA helicase with ATPase and RNA helicase functions.
  • eIF4A is vital for cap-dependent translation initiation, a process frequently dysregulated in carcinoma signal transduction.
  • Elevated eIF4A expression correlates with cancer progression, particularly in leukemia.

Purpose of the Study:

  • To elucidate the functional role of eIF4A in biological processes.
  • To review the development of small-molecule inhibitors targeting eIF4A for cancer therapy.

Main Methods:

  • Review of existing literature on eIF4A function and its role in cancer.
  • Analysis of preclinical data for eIF4A-targeting small-molecule inhibitors.

Main Results:

  • eIF4A's critical involvement in mRNA translation initiation and cancer-related pathways is confirmed.
  • Preclinical studies demonstrate the efficacy of various small-molecule inhibitors targeting eIF4A in cancer models.

Conclusions:

  • eIF4A is a significant therapeutic target for various cancers due to its role in translation.
  • The development of eIF4A inhibitors represents a promising strategy for novel anti-cancer drug discovery.
Keywords:
ATPase.eIF4AeIF4A inhibitorsleukemiaprognosistherapeutic target

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.3K
Identification of Protein Interacting Partners Using Tandem Affinity Purification10:02

Identification of Protein Interacting Partners Using Tandem Affinity Purification

Published on: February 25, 2012

37.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K